drugset / Trial / NCT02105012

Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma

NCT02105012

Phase 2 Completed 147 enrolled Pearl Therapeutics, Inc.
RandomizedCrossoverDouble-blindTreatment

Summary

Study to assess the efficacy and safety of four doses of budesonide inhalation aerosol (BD MDI, PT008) relative to placebo MDI in adult subjects with mild to moderate persistent asthma.

Timeline

Start
2014-04-01
Primary completion
2015-09-01
Completion
2015-09-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Budesonide Small molecule 40 ug Inhaled
Subject Budesonide Small molecule 80 ug Inhaled
Subject Budesonide Small molecule 160 ug Inhaled
Subject Budesonide Small molecule 320 ug Inhaled

Indications